Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


5th World Congress on Cancer Therapy

Atlanta, USA

Jayalakshmi Sridhar

Xavier University of Louisiana, USA

Title: Identifi cation of Quinones as growth inhibitors of Trastuzumab resistant breast cancer cells


Biography: Jayalakshmi Sridhar


In 2013, the number of new cases of breast cancer in the US was 234, 580 and ~1.7 million worldwide. Despite the advances in early detection and treatment of breast cancer, about 30% of patients with early stage breast cancer have recurrent disease where resistance to therapy is common and expected. HER2 is overexpressed in 20-40% of invasive breast cancer, and 12-24% of these patients develop resistance within 6 months for the widely used therapy trastuzumab. HER2 oncogenic variant HER2 16 has been shown to promote receptor dimerization, cell invasion and also trastuzumab resistance of NIH3T3 and MCF-7 tumor cells lines. We have identifi ed several naphthoquinones that show growth inhibition of the MCF-7 HER216 cell lines with a signifi cantly higher potency than the present clinically used tyrosine kinase inhibitor lapatinib. Th ese compounds also inhibit auto-phosphorylation of the Y1248 and Y1068 residues of HER2 and EGFR, respectively.